Literature DB >> 17547830

Interventions for body habitus changes associated with HIV infection and its treatment.

Pablo Tebas1.   

Abstract

Lipodystrophy and its two components lipo-accumulation and lipoatropy are very common among individuals with HIV infection on treatment, especially among those who started therapy in the late 1990s and early 2000s. This review discusses the current management of these complications of HIV and its treatment. For the purpose of clarity in this review, we have divided the interventions according to the predominant phenotype of the individual.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17547830     DOI: 10.1007/s11904-007-0013-x

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  47 in total

1.  Short-term exercise training improves body composition and hyperlipidaemia in HIV-positive individuals with lipodystrophy.

Authors:  S P Jones; D A Doran; P B Leatt; B Maher; M Pirmohamed
Journal:  AIDS       Date:  2001-10-19       Impact factor: 4.177

2.  Use of ultrasonography-assisted liposuction for the treatment of human immunodeficiency virus-associated enlargement of the dorsocervical fat pad.

Authors:  P J Piliero; M Hubbard; J King; J J Faragon
Journal:  Clin Infect Dis       Date:  2003-10-13       Impact factor: 9.079

3.  Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting.

Authors:  Viva W Tai; Morris Schambelan; Heather Algren; Clara Shayevich; Kathleen Mulligan
Journal:  Clin Infect Dis       Date:  2002-10-23       Impact factor: 9.079

4.  A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation.

Authors:  Julian Falutz; Soraya Allas; Donald Kotler; Melanie Thompson; Polyxeni Koutkia; Jeanine Albu; Benoit Trottier; Jean-Pierre Routy; Pierre Cote; Thierry Abribat; Steven Grinspoon
Journal:  AIDS       Date:  2005-08-12       Impact factor: 4.177

Review 5.  Poly-L-lactic acid.

Authors:  Caroline M Perry
Journal:  Am J Clin Dermatol       Date:  2004       Impact factor: 7.403

6.  Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients.

Authors:  Donald P Kotler; Norma Muurahainen; Carl Grunfeld; Christine Wanke; Melanie Thompson; Michael Saag; Daena Bock; Gregg Simons; Joseph M Gertner
Journal:  J Acquir Immune Defic Syndr       Date:  2004-03-01       Impact factor: 3.731

7.  Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection.

Authors:  Ellen S Engelson; Marshall J Glesby; Douglas Mendez; Jeanine B Albu; Jack Wang; Steven B Heymsfield; Donald P Kotler
Journal:  J Acquir Immune Defic Syndr       Date:  2002-08-01       Impact factor: 3.731

8.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.

Authors:  A Carr; K Samaras; S Burton; M Law; J Freund; D J Chisholm; D A Cooper
Journal:  AIDS       Date:  1998-05-07       Impact factor: 4.177

9.  Differential effects of metformin and exercise on muscle adiposity and metabolic indices in human immunodeficiency virus-infected patients.

Authors:  Susan D Driscoll; Gary E Meininger; Karin Ljungquist; Colleen Hadigan; Martin Torriani; Anne Klibanski; Walter R Frontera; Steven Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2004-05       Impact factor: 5.958

10.  Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.

Authors:  Grace A McComsey; Douglas J Ward; Siegrid M Hessenthaler; Michael G Sension; Peter Shalit; J Tyler Lonergan; Robin L Fisher; Vanessa C Williams; Jaime E Hernandez
Journal:  Clin Infect Dis       Date:  2003-12-18       Impact factor: 9.079

View more
  1 in total

Review 1.  Chemokine receptor 5 knockout strategies.

Authors:  Paula Cannon; Carl June
Journal:  Curr Opin HIV AIDS       Date:  2011-01       Impact factor: 4.283

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.